Ryan Phillips
Radiation Oncology · Rochester, MNNPI 1184011348
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $756 of the $1,048 with a category attached, or 72.2%. Novartis accounts for 84.1% of it on its own, with 1 other manufacturer making up the rest.
Across 5 payments — averaging $209.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$882
- Reflexion Medical, Inc.$166
Across 4 payments — averaging $176,202 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$705K
What the payments were for
- Travel & lodging$29228%
- Food & beverage$75672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $882 |
| Reflexion Medical, Inc. | 1 | $166 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,048 in reported general payments places this provider in the 80th percentile of 128 radiation oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 16 | $181 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Rochester
- Aadel ChaudhuriRochester$37K
- Brian DavisRochester$28K
- Jann SarkariaRochester$26K
- Daniel ChamberlainRochester$21K
- Kenneth MerrellRochester$14K
- Meng WelliverRochester$13K
- Tyler WilhiteRochester$5K
- Aurelie GarantRochester$4K
- Sean ParkRochester$4K
- Bryan TraughberRochester$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.